Table 2 Characteristics of the cohorts of patients with CocaineUD before and after propensity-score matching performed on all listed variables.
From: Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US
Before propensity-score matching | After propensity-score matching | |||||
|---|---|---|---|---|---|---|
CocaineUD | COVID-19 (+) cohort | COVID-19 (−) Cohort | SMD | COVID-19 (+) cohort | COVID-19 (−) Cohort | SMD |
Total number | 23,687 | 192,335 | 22,420 | 22,420 | ||
Age at index (years, mean ± SD) | 46.3 ± 14.3 | 45.2 ± 14.0 | 0.08 | 46.1 ± 14.3 | 46.2 ± 14.0 | 0.006 |
Sex (%) | ||||||
Female | 41.4 | 37.8 | 0.07 | 41.1 | 40.9 | 0.004 |
Male | 58.6 | 62.1 | 0.07 | 58.9 | 59.1 | 0.004 |
Ethnicity (%) | ||||||
Hispanic/Latinx | 10.3 | 8.5 | 0.06 | 10.2 | 10.6 | 0.01 |
Not Hispanic/Latinx | 68.2 | 63.5 | 0.09 | 68.1 | 68.3 | 0.004 |
Unknown | 21.5 | 27.9 | 0.15a | 21.6 | 21.1 | 0.01 |
Race (%) | ||||||
Asian | 0.7 | 0.8 | 0.02 | 0.6 | 0.6 | 0.008 |
Black | 36.6 | 36.7 | 0.002 | 36.8 | 37.0 | 0.004 |
White | 51.5 | 50.5 | 0.02 | 51.1 | 51.1 | 0.001 |
Unknown | 10.3 | 11.2 | 0.03 | 10.5 | 10.5 | 0.001 |
Adverse socioeconomic determinants of health (%) | 32.2 | 19.5 | 0.29a | 31.7 | 31.7 | 0.001 |
Endocarditis related comorbidities and procedures (%) | ||||||
Congenital heart diseases | 3.8 | 1.88 | 0.12a | 3.7 | 3.6 | 0.005 |
Gingivitis and periodontal diseases | 3.8 | 2.4 | 0.08 | 3.6 | 3.6 | 0.001 |
Dental caries | 11.9 | 8.2 | 0.12a | 11.8 | 11.5 | 0.01 |
Rheumatic heart diseases | 6.2 | 2.5 | 0.18a | 5.8 | 5.9 | 0.001 |
Rheumatic fever | 0.2 | 0.1 | 0.03 | 0.2 | 0.2 | 0.003 |
Hemodialysis | 1.5 | 0.4 | 0.08 | 1.4 | 1.6 | 0.01 |
Surgical procedures involving heart and artery | 11.4 | 6.0 | 0.19a | 11.2 | 11.4 | 0.005 |
Cardiac catheterization | 6.0 | 3.0 | 0.15a | 5.6 | 5.7 | 0.005 |
Cardiac and vascular implants and grafts | 9.0 | 4.8 | 0.17a | 8.6 | 8.7 | 0.002 |
Opioid use disorder | 31.7 | 25.6 | 0.13a | 31.6 | 32.2 | 0.01 |
Other potential cardiovascular risk factors | ||||||
Obesity and overweight | 28.7 | 15.9 | 0.31a | 27.9 | 27.6 | 0.006 |
Type 2 diabetes | 25.9 | 15.3 | 0.26a | 25.2 | 25.2 | 0.001 |
Hypertension | 49.8 | 35.1 | 0.30a | 48.9 | 48.8 | 0.003 |
Cancer | 33.9 | 20.0 | 0.32a | 32.4 | 31.6 | 0.02 |
Disorders involving the immune mechanisms | 4.6 | 2.2 | 0.14a | 4.3 | 4.3 | 0.001 |
Atrial fibrillation and flutter | 7.5 | 3.7 | 0.17a | 7.3 | 7.4 | 0.006 |
HIV | 6.6 | 4.7 | 0.09 | 6.3 | 6.1 | 0.007 |
Viral hepatitis | 20.7 | 15.6 | 0.13a | 20.5 | 20.3 | 0.004 |
Liver diseases | 21.7 | 12.4 | 0.25a | 20.9 | 20.8 | 0.002 |
Chronic kidney disease | 16.2 | 7.2 | 0.28a | 15.8 | 15.9 | 0.003 |
Tobacco use | 33.4 | 20.1 | 0.31a | 32.4 | 31.9 | 0.009 |
Medications | ||||||
Chemotherapy | 9.1 | 4.4 | 0.19a | 8.6 | 8.4 | 0.008 |
Corticosteroids | 43.9 | 24.8 | 0.41a | 43.2 | 42.8 | 0.006 |
Dexamethasone | 30.2 | 16.0 | 0.34a | 29.2 | 28.8 | 0.007 |
Immunosuppressants | 3.8 | 1.6 | 0.13a | 3.6 | 3.5 | 0.002 |
Antidepressants | 57.0 | 39.7 | 0.35a | 56.1 | 56.2 | 0.002 |
Antipsychotics | 39.8 | 28.2 | 0.25a | 39.5 | 40.0 | 0.009 |
Anticonvulsants | 47.0 | 31.4 | 0.32a | 46.3 | 46.2 | 0.001 |
CNS stimulants | 18.0 | 9.2 | 0.26a | 17.6 | 17.1 | 0.01 |
Other CNS medications | 38.8 | 24.8 | 0.31a | 38.0 | 37.8 | 0.005 |
EHR-documented COVID-19 vaccination | 4.2 | 0.1 | 0.29a | 0.4 | 0.4 | 0.008 |